A comprehensive view of Insulet Corp.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA approves Insulet’s Omnipod 5 tubeless automated insulin delivery system for kids two years old and older with type 1 diabetes; Omnipod 5 integrates Dexcom G6 CGM system to automatically adjust insulin, protect against high and low glucose levels

Sustainability & Social Responsibility: Insulet 2021 Sustainability Report

Insulet releases 2021 sustainability report; highlights include 100% fulfillment of customer orders via dual and local sourcing while in Europe, UK, Canada, Insulet diverted over 135 metric tons of Omnipod Pods from landfills via product takeback programs

Insulet reports Q1 net income of US$27.8M from US$0.0M a year ago, with revenue up 17.1% year-over-year at US$295.4M; US revenue of Omnipod 5 automated insulin delivery system up 21.5% after limited launch in country, with full market release this year

Insulet names Jim Hollingshead, Ph.D. as President, CEO, to succeed Shacey Petrovic, who is stepping down from the position on June 1; Dr. Hollingshead currently serves as President of Sleep and Respiratory Care at ResMed, Inc.

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count